Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer
Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer
复制标题
DOI：
10.3816/ccc.2008.n.027
复制
发表时间：
2008-05-01
影响因子：
3.4
通讯作者：
Genther, Renee
中科院分区：
文献类型：
--
作者：
Cartwright, Thomas H.;Genther, Renee
单克隆抗体（MoAb）给药可导致不同级别的输注反应;西妥昔单抗输注后约3%的患者发生重度反应（约0.1%的患者发生死亡）。我们报告了一例对西妥昔单抗（一种鼠单抗）有严重反应的患者，然后接受帕尼单抗（一种人单抗）治疗，并耐受了该药物，无任何输注反应。
The administration of monoclonal antibodies (MoAbs) can result in infusion reactions of various grades; severe reactions are seen in approximately 3% of patients after infusions of cetuximab (fatalities occur in approximately 0.1% of patients). We report a case of a patient who had a severe reaction to cetuximab (a murine MoAb) who then received panitumumab (a human MoAb) and tolerated it without any infusion reaction.